Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

Circulation

Volumn 100, Issue 15, 1999, Pages 1593-1601

  Antman, Elliott M ^a   McCabe, Carolyn H ^a   Gurfinkel, Enrique P ^b   Turpie, Alexander G G ^c   Bernink, Peter J L M ^d   Salein, Diana ^e   Bayes De Luna, Antonio ^f   Fox, Kim ^g   Lablanche, Jean Marc ^h   Radley, David ⁱ   Premmereur, Jerome ⁱ   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^c MCMASTER UNIVERSITY   (Canada)

^d MARTINI HOSPITAL   (Netherlands)

^e Clinical Research Services   (Germany)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ SANOFI   (France)

Author keywords

Angina; Anticoagulants; Coronary disease; Heparin

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; UNSTABLE ANGINA PECTORIS;

EID: 0032870952     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.15.1593     Document Type: Article

References (29)

1. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769-771.
2. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594-599.
3. Weitz JI. Activation of blood coagulation by plaque rupture: mechanisms and prevention. Am J Cardiol. 1995;75:23-25.
4. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287-289.
5. Ardissino D, Merlini PA, Gamba G, Barberis P, Demicheli G, Testa S, Colombi E, Poli A, Fetiveau R, Montemartini C. Thrombin activity and early outcome in unstable angina pectoris. Circulation. 1996;93: 1634-1639.
6. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannuccio PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
7. Theroux P, Ouimet H, McCans J, Latour J-G, Joly G, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 1988; 319:1105-1111.
8. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
9. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
10. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993;88:2045-2048.
11. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA. 1996;276:811-815.
12. Cairns J, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Chest. 1995;108: 380S-400S.
13. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89: 81-88.
14. Barrowcliffe T, Johnson E, Thomas D. Low Molecular Weight Heparin. Chicester, UK: John Wiley & Sons; 1992.
15. Bounameaux H. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembotic Disease. New York, NY: Marcel Dekker Inc; 1994.
16. Agnelli G. Pharmacological activities of heparin chains: should our past knowledge be revised? Haemostasis. 1996;26:2-9.
17. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
18. FRISC Study Group. Low molecular weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Lancet. 1996;347: 561-568.
19. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K, for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997;96:61-68.
20. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
21. The TIMI 11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cordial. 1997;29: 1474-1482.
22. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
23. Cohen M, Bigonzi F, Lelouer V, Gosset F, Fromell GJ, Goodman S. One year follow-up of the ESSENCE trial (Enoxaparin verus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction). J Am Coll Cardiol. 1998;31:79A. Abstract.
24. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
25. The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338: 1498-1505.
26. The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
27. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patient with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
28. Topol EJ, Byzova TV, Plow ER. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227-231.
29. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-Essence meta-analysis. Circulation. 1999;100:1602-1608.